Τίτλος:
Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Several lines of evidence suggest that binding SARS-CoV-2 antibodies such as anti-SARSCoV-2 RBD IgG (anti-RBD) and neutralising antibodies (NA) are correlates of protection against SARS-CoV-2, and the correlation of anti-RBD and NA is very high. The effectiveness (VE) of BNT162b2 in preventing SARS-CoV-2 infection wanes over time, and this reduction is mainly associated with waning immunity, suggesting that the kinetics of antibodies reduction might be of interest to predict VE. In a study of 97 health care workers (HCWs) vaccinated with the BNT162b2 vaccine, we assessed the kinetics of anti-RBD 30–250 days after vaccination using 388 individually matched plasma samples. Anti-RBD levels declined by 85%, 92%, and 95% at the 4th, 6th, and 8th month from the peak, respectively. The kinetics were estimated using the trajectories of anti-RBD by various models. The restricted cubic splines model had a better fit to the observed data. The trajectories of anti-RBD declines were statistically significantly lower for risk factors of severe COVID-19 and the absence of vaccination side effects. Moreover, previous SARS-CoV-2 infection was associated with divergent trajectories consistent with a slower anti-RBD decline over time. These results suggest that anti-RBD may serve as a harbinger for vaccine effectiveness (VE), and it should be explored as a predictor of breakthrough infections and VE. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Hatzakis, A.
Karabinis, A.
Roussos, S.
Pantazis, N.
Degiannis, D.
Chaidaroglou, A.
Petsios, K.
Pavlopoulou, I.
Tsiodras, S.
Paraskevis, D.
Sypsa, V.
Psichogiou, M.
Λέξεις-κλειδιά:
C reactive protein; diltiazem; immunoglobulin G; tozinameran, adult; antigen binding; Article; blood sampling; chemiluminescence immunoassay; controlled study; exponential model; female; health care personnel; human; immune response; immunogenicity; immunoglobulin blood level; immunosuppressive treatment; kinetics; male; model selection; nonhuman; power law model; questionnaire; restricted cubic splines model; Severe acute respiratory syndrome coronavirus 2; statistical analysis; vaccination
DOI:
10.3390/vaccines10020285
